NCT05336071

The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects

Study on Bioavailability Study of INS068 Injection by Subcutaneous Injection of New and Old Formulations in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 24 healthy male subjects. Subjects will receive INS068 injection on Day1 and Day8.

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	INS068 injection	Group A subjects were injected formulation T and formulation R of INS068 injection at Day1 and Day8.
DRUG	INS068 injection	Group B subjects were injected formulation R and formulation T of INS068 injection at Day1 and Day8.

Timeline

• Start date: 2022-05-12
• Primary completion: 2022-05-26
• Completion: 2022-06-02
• First posted: 2022-04-20
• Last updated: 2023-06-08

Locations

1 site across 1 country: China